Search clinical trials for: caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam

Total 56 results

University Hospital, Basel, Switzerland

Completed

Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes

Pharmacokinetics | Cytochrome

Switzerland
University of Southern Denmark
Odense University Hospital

Terminated

Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes

Cytochrome P450 Phenotype and Genotype Metrics

Denmark
University of Cologne
Umm Al-Qura University

Completed

Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein

AOD Effects and Consequences

Germany
Pfizer

Completed

Drug-Drug Interaction Study With PF-05089771

Healthy

Belgium
Amgen

Active, not recruiting

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States
GlaxoSmithKline

Completed

A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects

Healthy Subjects | Anaemia

Australia
Boehringer Ingelheim

Completed

The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)

Healthy

Germany
Centre hospitalier de l'Université de Montréal...
Canadian Institutes of Health Research (CIHR)

Completed

Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects

Type 2 Diabetes

Canada
Sanofi

Completed

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Solid Tumor

United States
AstraZeneca
Quintiles, Inc.

Completed

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Solid Tumours

United States
Chonbuk National University Hospital

Completed

Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers

Healthy

Korea, Republic of
Novartis Pharmaceuticals

Completed

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Advanced Solid Tumors, Excluding Breast Cancer

United States
Daiichi Sankyo, Inc.
Medpace, Inc.

Completed

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Solid Tumors

United States
Corcept Therapeutics

Completed

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Healthy

United States
LEO Pharma

Completed

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Atopic Dermatitis

United States, France, Netherlands
ViiV Healthcare

Completed

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

HIV Infections

United States
AstraZeneca

Completed

AZD2066 Cocktail Study

Chronic Pain

United Kingdom
Repros Therapeutics Inc.

Completed

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

Drug Interactions

United States
AstraZeneca

Completed

Drug Interaction Study Between AZD3480 and Cytochrome P450 (Cocktail)

Alzheimer's Disease | Metabolism

Sweden
University of Southern Denmark
SignaTope GmbH, Germany

Completed

Flucloxacillin as an Inducer of CYP-enzymes

Healthy Volunteers | Drug Drug Interaction

Denmark
Pfizer
Pierre Fabre Laboratories

Active, not recruiting

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Melanoma

United States, Spain, Belgium, Canada, Netherlands
University of Southern Denmark

Terminated

Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Denmark
Bristol-Myers Squibb

Completed

Drug Interaction Study With a Potential Alzheimer's Disease Compound

Alzheimer Disease

United States
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Plaque Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Suspended

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Germany, United States, United Kingdom, Belgium
Boehringer Ingelheim

Recruiting

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Liver Cirrhosis

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood

Healthy

Germany
AbbVie
Boehringer Ingelheim

Completed

This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

Psoriasis

Germany
Regeneron Pharmaceuticals
Sanofi

Completed

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Atopic Dermatitis

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

China
University of Washington
National Institute of General Medical Sciences (NIGMS)

Completed

The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity (FLUOXETINE)

Healthy Volunteers | Drug-Drug Interaction
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects

Healthy

Belgium
Takeda

Withdrawn

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Crohn Disease | Colitis, Ulcerative

United States
Jules Desmeules

Completed

Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail

Drug Interaction

Switzerland
Boehringer Ingelheim

Completed

Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers

Healthy
Radboud University Medical Center

Completed

Phenotyping of High Dose Rifampicin (PHENORIF)

Tuberculosis

South Africa
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

Germany, Korea, Republic of, South Africa, Moldova, Republic of
Bristol-Myers Squibb

Completed

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

Transplant Rejection

United States
Pfizer

Completed

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

Healthy Participants

United States
Boehringer Ingelheim

Completed

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

Healthy
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Psoriasis

United States
R-Pharm International, LLC
IQVIA RDS Ireland Ltd; Thermo Fisher Scientific FS

Completed

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Rheumatoid Arthritis

Bulgaria, Moldova, Republic of
University Hospital, Geneva

Unknown

Drug Metabolism and Antidepressant (METADEP)

Depression

Switzerland
Jules Desmeules

Completed

Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot

Healthy Volunteers

Switzerland
zr Pharma & GmbH

Completed

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib (DDI)

Neoplasms

Poland
Inje University

Completed

Development of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human

Healthy
Turku University Hospital

Completed

Dabigatran in an Interaction Probe Drug Cocktail (D-cocktail)

Healthy Volunteers

Finland
Merck Sharp & Dohme LLC

Completed

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Infectious Disease
Abliva AB

Completed

Drug-drug Interaction Study of KL1333 in Healthy Subjects

Mitochondrial Disease

United Kingdom
Boehringer Ingelheim

Completed

Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers

Healthy

3

Subscribe